ClinicalTrials.gg
CompletedNCT03557671Updated Nov 4, 2020

Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins

An interventional study of rice formula and placebo in Cow Milk Allergy, sponsored by United Pharmaceuticals. Completed at 4 sites in 3 countries. Open to participants aged 1 Month to 36 Months. Per ClinicalTrials.gov, last updated 2020-11-04.

Sponsored by United Pharmaceuticals · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
1 Month to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Milk Hypersensitivity with a site in France — 1 open to participants now, 1 under way, none of them phase 3. Milk Hypersensitivity · France.

Enrollment
5th of 10
72 · median 62
Started
2018
the only one that year
No phase
8 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
3 of 12
United Pharmaceuticals

Among the 12 studies in Milk Hypersensitivity with a site in France, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 8 with no phase, and was the 10th registered.

Milk Hypersensitivity

147 studies on the registry are indexed under Milk Hypersensitivity; 26 are open to participants now.

Browse Milk Hypersensitivity studies →

Open to participants now

1 of the 12 studies in Milk Hypersensitivity with a site in France is open now. Recruiting first, the newest first:

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 16 Milk Hypersensitivity studies recruiting now, 1 (6%) sets no upper age limit and 15 (94%) stop at 75 or younger; 15 take children under 18; 1 takes healthy volunteers.

This study: 1 Month to 36 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Milk Hypersensitivity with a site in France, or all of them as a file.
02

Study summary

The aim of this study is to show the hypoallergenicity of a new thickened rice based formula (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by the American Academy of Pediatrics, in subjects with IgE-mediated CMA and in subjects with non-IgE-mediated CMA.

Read the detailed description

The study is made of 2 different steps : 1st step is a double blind randomised food challenge where the new formula is compared to a placebo.

The second part of the trial consists in an open phase during which all infants will be fed with the study formula.

03

Conditions studied

  • Cow Milk Allergy

Browse trials for

04

Who can participate

Ages eligible
1 Month to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • with suspected CMA or with a CMA diagnosed by a DBPCFC performed in the last 2 months prior to inclusion
  • free of clinical allergic symptoms for at least one week (i.e. successfully fed an elimination diet);
  • whose parents signed the

Exclusion criteria

Exclusion Criteria:

  • mainly breast fed, drinking less than 250ml of formula/day, presenting any situation, which, according to the investigator, may interfere with the study participation or lead to a particular risk for the subject
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    TRHF - Placebo

    Each subjects will receive both TRHF and placebo formula during the 1st part of the study

    Dietary Supplement: rice formula · Dietary Supplement: placebo

  • Placebo comparator
    Placebo - TRHF

    Each subjects will receive both TRHF and placebo formula during the 1st part of the study

    Dietary Supplement: rice formula · Dietary Supplement: placebo

Interventions

  • Dietary supplementrice formula

    new rice based thickened formula

  • Dietary supplementplacebo

    formula previously tolerated by the subject - only for the 1st part of the study

06

What researchers measure

Primary outcomes

  1. hypoallergenicity

    the percentage of children tolerating the formula during the double blind placebo controlled food challenge (TRHF 2017 vs. placebo formula).

    Time frame: 7 days

Secondary outcomes

  1. Regurgitations

    assessed through Vandenplas score ranging from 0 (=less than 2 regurgitation episodes / day) to 6 (=Regurgitation of the complete volume after each feeding)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  2. Vomiting

    (on a 4 level scale)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  3. Abdominal pain

    (severity on a 4 level scale)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  4. Bloating and gas

    (severity on a 4 level scale)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  5. Stool consistency

    assessed through Bristol Stools Form Scale from Type A ( Separate hard lumps, like nuts (hard to pass)) to Type G (Watery, not solid pieces - entirely liquid )

    Time frame: 1, 2, 3, 4, 5 and 6 months

  6. Stool frequency

    (number of stool per day or per week)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  7. Blood in stools

    (presence/absence)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  8. Sleeping time over 24h satisfaction

    (presence/absence)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  9. Unexplained crying

    (yes/no)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  10. Respiratory symptoms

    (severity on a 4 level scale)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  11. Urticaria

    (presence/absence)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  12. Angioedema

    (presence/absence)

    Time frame: 1, 2, 3, 4, 5 and 6 months

  13. Eczema

    severity assessed through SCORAD

    Time frame: 1, 2, 3, 4, 5 and 6 months

  14. Weight

    expressed in kg and in z scores according to the World Health Organization (WHO) Child Growth Standards

    Time frame: 1, 2, 3, 4, 5 and 6 months

  15. Height

    expressed in cm and in z scores according to the WHO Child Growth Standards

    Time frame: 1, 2, 3, 4, 5 and 6 months

  16. BMI

    expressed in value and z scores according to the WHO Child Growth Standards

    Time frame: 1, 2, 3, 4, 5 and 6 months

  17. Head circumference

    expressed in cm and in z scores according to the WHO Child Growth Standards

    Time frame: 1, 2, 3, 4, 5 and 6 months

  18. Number of patients with treatment emergent Adverse Events

    Time frame: 1, 2, 3, 4, 5 and 6 months

07

Study locations

4 sites
  • CHR Namur
    Namur, Belgium
  • Hôpital Saint Vincent de Paul - GHICL
    Lille, 59000, France
  • Hopital Trousseau
    Paris, France
  • University of Naples Federico II
    Naples, Italy
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Sep 2020, 24 months.

Of 34 interventional studies with no phase under Milk Hypersensitivity, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 48. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
Jun 15, 2018
StartActual
Aug 23, 2018
Primary completionActual
Sep 21, 2020
CompletionActual
Sep 21, 2020
Last update
Nov 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03557671
Lead sponsor
United Pharmaceuticals
Collaborators
Statitec
Responsible party
Sponsor
First posted
Jun 15, 2018
Start date
Aug 23, 2018
Primary completion
Sep 21, 2020
Completion
Sep 21, 2020
Last update
Nov 4, 2020

Study contacts

Roberto Berni Canani
study director · University Federico II

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion